Trial NCT04404140

View at ClinicalTrials.gov 
Org. Study IDs: CO41792
Secondary IDs: 2019-004591-19

Last trial update was posted on 2023-10-17

MeSH Interventions

Atezolizumab Docetaxel Ipatasertib

MeSH Conditions

Prostatic Neoplasms Prostatic Neoplasms, Castration-Resistant

Other Conditions

Castration-Resistant Prostatic Cancer

Stopping Reasons

Despite many risk-minimization strategies, the combination of ipatasertib, atezolizumab and docetaxel was challenging due to multiple study treatment modifications required to manage toxicity, making further enrollment inappropriate.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID